Pipeline

We are focused on the treatment of hemophilia using our high potency coagulation factors that promote blood clotting. We initiated a clinical trial of our Factor IX candidate in individuals with hemophilia B in June of 2017. The Phase 2 portion of a Phase 2/3 clinical trial of our Factor VIIa candidate in individuals with hemophilia A or B with inhibitors was initiated in January of 2018.

Next Generation Hemostasis Programs

Hemophilia A or B with Inhibitors
Phase 2/3
    
Drug Candidate
Indication
Research
Preclinical
Phase 1/2
Phase 2/3

*(formerly known as CB 813d)
**(formerly known as CB 2679d/ISU304)

Anti-Complement Program Available for Partnering